Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 812345...Last »

Lilly’s Longtime CEO to Retire, Successor Named

John Lechleiter, the longtime CEO at Eli Lilly, will retire at the end of 2016. David Ricks, senior VP and president of Lilly Bio-Medicines, has been tapped as the successor.

Read More »

Pfizer Wins Bid; Buys BIND Therapeutics Bankruptcy Assets for $40 Million

As reported on July 25, Cambridge, Massachusetts-based Bind Therapeutics was selling off most of its assets as part of bankruptcy proceedings. Pfizer had been approved as the stalking horse bidder, with a floor bid of $20 million in cash, as well as taking on various contractual liabilities. Two other unidentified companies joined the auction. BIND now has announced that Pfizer is the winner, with a bid of $40 million.

Read More »

One in Two American Adults Misuse Their Prescription Drugs, Finds Analysis of More Than Three Million Lab Tests from Quest Diagnostics

The majority of American adults taking opioids and other commonly prescribed medications use them in ways that put their health at risk – including potentially dangerous combinations with other drugs – according to a new study from Quest Diagnostics, the world’s leading provider of diagnostic information services.

Read More »

Centene says it does not have network for Aetna’s assets

Centene Corp.’s chief executive said the mid-cap health insurer did not have the network for the Medicare Advantage assets Aetna Inc. or other large managed care companies are looking to sell as part of the industry-wide consolidation.

Read More »

Lilly sales beat estimates, helped by newer drugs

Eli Lilly reported better-than-expected second-quarter 2016 sales and predicted average annual revenue growth of at least 5 percent through the end of the decade.

Read More »

Phase III Trials Halted for Lung Cancer Drug Gilotrif

Boehringer Ingelheim was forced to halt two Phase III trials for lung cancer drug Gilotrif following the advice of a data monitoring committee, Pharma Times reported.

Read More »

Celgene drug fails to extend survival in lymphoma study

Celgene Corp. said its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.

Read More »

U.S. health officials update Zika transmission and testing guidance

U.S. health officials issued updated recommendations for preventing and testing for Zika infection, warning that the virus can be transmitted through unprotected sex with an infected female partner.

Read More »

FDA Approves VIEKIRA XR for HCV Infection

FDA approves the first all-oral, co-formulated treatment containing the three direct-acting antiviral components of VIEKIRA PAK for genotype 1 chronic hepatitis C virus (HCV) infection.

Read More »

FDA rejects post-operative eye pain treatment

Drug developer Ocular Therapeutix Inc said the U.S. Food and Drug Administration had denied approval for its treatment for post-operative eye pain.

Read More »

FDA Lifts Clinical Hold On CGF166

GenVec was notified by its collaborator Novartis that FDA has lifted the clinical hold on the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss.

Read More »

AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

AbbVie and Bristol-Myers Squibb announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC).

Read More »

Following Revelations of ‘Flawed Studies’ in Clinical Trials, EMA Recommends Suspending Drugs; Many of Which Belong to Novartis AG and Teva

The European Medicines Agency recommended suspending the sale of dozens of generic medications, including several made by Novartis AG and Teva, following concerns over “flawed” studies conducted at a research facility in India.

Read More »

Bankrupt BIND Therapeutics Reveals Two More Bidders Join Pfizer’s Stalking Horse Bid

On July 1, Cambridge, Massachusetts-based Bind Therapeutics announced that Pfizer had been approved as the stalking horse bidder for the majority of the company’s assets. The company has announced that two additional bidders had joined the auction.

Read More »

Malaria drug may help in cancer fight

An off-patent malaria drug could help to destroy cancer cells by making them more susceptible to radiotherapy, according to early research.

Read More »

‘Brain training’ cut dementia risk in healthy adults – U.S. study

A computerized brain training program cut the risk of dementia among healthy people by 48 percent, U.S. researchers said in reporting an analysis of the results of a 10-year study.

Read More »

400+ Women are Suing Drug Giant Merck & Co. Over Unequal Pay

Merck & Co. is under fire after more than 400 current and former female employees filed a $250 million class action lawsuit against the drug giant alleging gender discrimination and unequal pay.

Read More »

FDA raises concerns over Valeant’s eye drop

Valeant Pharmaceuticals International said U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida.

Read More »

Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA

Amgen and UCB announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Read More »

Scientists hunt ‘anti-evolution’ drugs in new cancer fight

Scientists are opening a new front in the war on cancer with plans to develop “anti-evolution” drugs to stop tumor cells from developing resistance to treatment.

Read More »

Page 2 of 812345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom